The Food and Drug Administration’s Office of Orphan Products Development (OOPD), in collaboration with the FDA Center for Drug Evaluation and Research (CDER), has launched a web-based educational tool for rare disease patients, advocacy groups, researchers and industry on various FDA-related topics.
Several topics are addressed, including the essentials of interacting with FDA and expanded access to products under development. FDA plans to develop additional topics in the future.
Above is the video introduction for the program by NORD President and CEO Peter L. Saltonstall. Visit FDA’s educational resource here.
